Precigen up as rare viral disease therapy meets main goal in early-stage study

Precigen

03/06/2024 16:04

** Shares of gene therapy developer Precigen  PGEN.O  rise
15.3% to $1.61 
    ** Co says its experimental gene therapy to treat a rare
viral disease met the main goal of an early-stage trial 
    ** The study enrolled a total of 38 patients who had three
or more surgeries in the prior 12 months
     ** Co says 51% of patients achieved a complete response,
requiring no surgeries in the 12 months following completion of
the treatment
    ** Adds, 86% of patients had a decrease in surgical
interventions in the year after treatment with the therapy
compared to the year prior to treatment
    ** The disease called recurrent respiratory papillomatosis
is caused by HPV infection that causes wart-like tumors in the
respiratory tract 
    ** The current standard of care for the disease is repeated
surgeries
    ** Co expects to submit a marketing application for the
therapy in the second half of this year 
    ** Including session moves, stock up 18.7% YTD  

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))